ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1678

CKD Is an Independent Risk Factor for Mortality in Elderly Patients Affected by COVID-19

Session Information

Category: Geriatric Nephrology

  • 1100 Geriatric Nephrology

Authors

  • Coelho, Venceslau Antonio, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
  • Aliberti, Marlon Jr, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
  • Silva, Thiago, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
  • Moreira, Felipe V., Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
  • Fortes, Otavio, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
  • Moyses, Rosa M.A., Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
  • Jacob Filho, Wilson, Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
  • Elias, Rosilene M., Universidade de Sao Paulo Hospital das Clinicas, Sao Paulo, São Paulo, Brazil
Background

COVID-19 infection, an acute respiratory syndrome caused by coronavirus, has recently emerged as a lethal pandemic. Many elderly patients have chronic kidney disease and several other comorbidities that are associated with worse outcomes. We hypothesized chronic kidney disease (CKD) in elderly patients is an independent risk of mortality and more severe COVID-19, even after adjustment for comorbidities.

Methods

This is a retrospective study, which enrolled 120 patients attended in a tertiary academic hospital divided into 2 groups, CKD (N=58) and non-CKD (N=62), according to eGFG < or ≥ 45ml/min/1.73m2. Charlson Comorbidity Index was used to evaluate comorbidities.

Results

Patients with CKD have a significantly (all p values <0.05) higher leucocytes count, C-reactive protein, troponin, and lactate dehydrogenase; they also presented lower albumin. There was no difference in body mass index (BMI), lymphocytes, hemoglobin, age, gender, Charlson Comorbidity Index, or duration of symptoms between groups. Patients with CKD presented more severe COVID-19, as evidenced by a higher inspiratory oxygen fraction (p=0.001), major radiological findings in computed tomography, ground-glass opacity (25% non-CKD and 53.1% CKD group presented lesion in >75% lung, p=0.042), and higher mortality (40.3% non-CKD vs. 75.9% CKD, p=0.0001). Logistic linear regression has revealed that CKD (RR 5.4, p=0.0001) was independent associated with mortality after adjustment for Charlson comorbidity Index (RR 1.2, p=0.034), age (p=0.551), gender (p=0.820) and BMI (p=0.941).

Conclusion

Elderly patients with CKD have a higher and independent risk for mortality after COVID-19. These patients should be closely monitored during this pandemic situation in order to avoid further damage.